Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer

Por King, Carly J., Woodward, Josha, Schwartzman, Jacob, Coleman, Daniel J., Lisac, Robert, Wang, Nicholas J., Van Hook, Kathryn, Gao, Lina, Urrutia, Joshua, Dane, Mark A., Heiser, Laura M., Alumkal, Joshi J.
Publicado no Oncotarget (2017)

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer

Por Coleman, Daniel J., Gao, Lina, Schwartzman, Jacob, Korkola, James E., Sampson, David, Derrick, Daniel S., Urrutia, Joshua, Balter, Ariel, Burchard, Julja, King, Carly J., Chiotti, Kami E., Heiser, Laura M., Alumkal, Joshi J.
Publicado no Sci Rep (2019)

BET Bromodomain Inhibition Blocks the Function of a Critical AR-Independent Master Regulator Network in Lethal Prostate Cancer

Por Coleman, Daniel J., Gao, Lina, King, Carly J., Schwartzman, Jacob, Urrutia, Joshua, Sehrawat, Archana, Tayou, Junior, Balter, Ariel, Burchard, Julja, Chiotti, Kami E., Derrick, Daniel S., Sun, Duanchen, Xia, Zheng, Heiser, Laura M., Alumkal, Joshi J.
Publicado no Oncogene (2019)

Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4

Por Coleman, Daniel J., Sampson, David A., Sehrawat, Archana, Kumaraswamy, Anbarasu, Sun, Duanchen, Wang, Yuzhuo, Schwartzman, Jacob, Urrutia, Joshua, Lee, Ahn R., Coleman, Ilsa M., Nelson, Peter S., Dong, Xuesen, Morrissey, Colm, Corey, Eva, Xia, Zheng, Yates, Joel A., Alumkal, Joshi J.
Publicado no Neoplasia (2020)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

Por Coleman, Daniel J., Van Hook, Kathryn, King, Carly J., Schwartzman, Jacob, Lisac, Robert, Urrutia, Joshua, Sehrawat, Archana, Woodward, Josha, Wang, Nicholas J., Gulati, Roman, Thomas, George V., Beer, Tomasz M., Gleave, Martin, Korkola, James E., Gao, Lina, Heiser, Laura M., Alumkal, Joshi J.
Publicado no Oncotarget (2016)

Copy Number Loss of 17q22 is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer

Por Guan, Xiangnan, Sun, Duanchen, Lu, Eric, Urrutia, Joshua A., Reiter, Robert Evan, Rettig, Matthew, Evans, Christopher P., Lara, Primo, Gleave, Martin, Beer, Tomasz M., Thomas, George V., Huang, Jiaoti, Aggarwal, Rahul R., Quigley, David A., Foye, Adam, Chen, William S., Youngren, Jack, Weinstein, Alana S., Stuart, Joshua M., Feng, Felix Y., Small, Eric J., Xia, Zheng, Alumkal, Joshi J.
Publicado no Clin Cancer Res (2020)

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function

Por Sehrawat, Archana, Gao, Lina, Wang, Yuliang, Bankhead, Armand, McWeeney, Shannon K., King, Carly J., Schwartzman, Jacob, Urrutia, Joshua, Bisson, William H., Coleman, Daniel J., Joshi, Sunil K., Kim, Dae-Hwan, Sampson, David A., Weinmann, Sheila, Kallakury, Bhaskar V. S., Berry, Deborah L., Haque, Reina, Van Den Eeden, Stephen K., Sharma, Sunil, Bearss, Jared, Beer, Tomasz M., Thomas, George V., Heiser, Laura M., Alumkal, Joshi J.
Publicado no Proc Natl Acad Sci U S A (2018)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

Por Alumkal, Joshi J., Sun, Duanchen, Lu, Eric, Beer, Tomasz M., Thomas, George V., Latour, Emile, Aggarwal, Rahul, Cetnar, Jeremy, Ryan, Charles J., Tabatabaei, Shaadi, Bailey, Shawna, Turina, Claire B., Quigley, David A., Guan, Xiangnan, Foye, Adam, Youngren, Jack F., Urrutia, Joshua, Huang, Jiaoti, Weinstein, Alana S., Friedl, Verena, Rettig, Matthew, Reiter, Robert E., Spratt, Daniel E., Gleave, Martin, Evans, Christopher P., Stuart, Joshua M., Chen, Yiyi, Feng, Felix Y., Small, Eric J., Witte, Owen N., Xia, Zheng
Publicado no Proc Natl Acad Sci U S A (2020)